Engineered Heart Repair

B. Fujita; W. H. Zimmermann

doi:10.1002/cpt.724

Engineered Heart Repair

B. Fujita, W. H. Zimmermann^*

^*Corresponding author for this work

Clinic of Cardiac and Thoracic Vascular Surgery

Georg August University Göttingen

9 Citations (Scopus)

Abstract

There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).

Original language	English
Journal	Clinical Pharmacology and Therapeutics
Volume	102
Issue number	2
Pages (from-to)	197-199
Number of pages	3
ISSN	0009-9236
DOIs	https://doi.org/10.1002/cpt.724
Publication status	Published - 01.08.2017

Funding

B.F. is supported by an Adumed Research stipend. W.H.Z. is supported by the DZHK (German Center for Cardiovascular Research), the German Federal Ministry for Science and Education (BMBF FKZ 13GW0007A (CIRM-ET3)), the German Research Foundation (DFG ZI 708/10-1; SFB 937 TP18, SFB 1002 TPs C04, S1; IRTG 1618 RP12), the European Union FP7 CARE-MI, the Foundation Leducq, and the National Institutes of Health (U01HL099997).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/cpt.724

Cite this

@article{d30e282086c448cc87f22c9d8a142ef6,

title = "Engineered Heart Repair",

abstract = "There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).",

author = "B. Fujita and Zimmermann, \{W. H.\}",

note = "Funding Information: B.F. is supported by an Adumed Research stipend. W.H.Z. is supported by the DZHK (German Center for Cardiovascular Research), the German Federal Ministry for Science and Education (BMBF FKZ 13GW0007A (CIRM-ET3)), the German Research Foundation (DFG ZI 708/10-1; SFB 937 TP18, SFB 1002 TPs C04, S1; IRTG 1618 RP12), the European Union FP7 CARE-MI, the Foundation Leducq, and the National Institutes of Health (U01HL099997). Publisher Copyright: {\textcopyright} 2017 American Society for Clinical Pharmacology and Therapeutics Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "2017",

month = aug,

day = "1",

doi = "10.1002/cpt.724",

language = "English",

volume = "102",

pages = "197--199",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Engineered Heart Repair

AU - Fujita, B.

AU - Zimmermann, W. H.

N1 - Funding Information: B.F. is supported by an Adumed Research stipend. W.H.Z. is supported by the DZHK (German Center for Cardiovascular Research), the German Federal Ministry for Science and Education (BMBF FKZ 13GW0007A (CIRM-ET3)), the German Research Foundation (DFG ZI 708/10-1; SFB 937 TP18, SFB 1002 TPs C04, S1; IRTG 1618 RP12), the European Union FP7 CARE-MI, the Foundation Leducq, and the National Institutes of Health (U01HL099997). Publisher Copyright: © 2017 American Society for Clinical Pharmacology and Therapeutics Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).

AB - There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).

UR - https://www.scopus.com/pages/publications/85021411911

U2 - 10.1002/cpt.724

DO - 10.1002/cpt.724

M3 - Journal articles

C2 - 28661033

AN - SCOPUS:85021411911

SN - 0009-9236

VL - 102

SP - 197

EP - 199

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 2

ER -

Engineered Heart Repair

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this